ME3221, a Surmountable Angiotensin AT1-Receptor Antagonist, Prevents Hypertensive Complications in Aged Stroke-Prone Spontaneously Hypertensive Rats

The Japanese Journal of Pharmacology

Mikio Yamamoto¹  Chen Hui¹  Mitsuhiro Abe¹  Jun Nagura¹  Mitsugu Hachisu¹  Fukio Konno¹  Sumie Yasuda¹ 

[1] Pharmaceutical Research Center, Meiji Seika Kaisha, Ltd.

关键词: ME3221;    Angiotensin AT1-receptor antagonist;    Stroke-prone spontaneously hypertensive rat;   

DOI  :  10.1254/jjp.71.39

学科分类：药理学

来源: Nihon Yakuri Gakkai Henshuubu / Japanese Pharmacological Society

【 摘 要 】

References(30)Cited-By(3)The protective effects of ME3221, 3-met hoxy-2, 6-dimethyl-4-[[2''-(1H-tetrazol-5-yl)-1, 1''-biphenyl-4-yl]methoxy] pyridine, on aged (32-week-old) stroke-prone spontaneously hypertensive rats (SHRSP) were studied following long-term (for 8 months) oral administration. At a dose of 10 mg/kg/day, ME3221 suppressed the mortality and the hypertensive complications observed in control SHRSP: cerebral apoplexy (hemorrhage, and spongeform and malacia in the cerebral cortex), increased proteinuria, and total N-acetyl-β-D-glucosaminidase activity, and cardiac hypertrophy and pleural effusion. The protective activity of ME3221, a surmountable angiotensin AT1-receptor antagonist, was comparable to losartan, an insurmountable AT1-antagonist, and also to enalapril, an angiotensin-converting enzyme inhibitor. In addition, ME3221 reduced the systolic blood pressure more effectively than the two reference drugs.

【 授权许可】

Unknown